|
Market Closed -
Nasdaq
05:00:00 27/02/2026 HKT
|
5-day change | 1st Jan Change | ||
| 72.82 USD | +0.03% |
|
-.--% | +0.96% |
| 10-22 | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 10-19 | Pharma sector doubles down on AI to slash costs, timelines | RE |
| Market Cap | 11.3B 10.08B 9.28B 8.42B 15.96B 1,059B 16.36B 111B 44.25B 567B 42.41B 41.5B 1,786B | P/E 2024 |
-10.1x | P/E 2025 | -14.5x |
|---|---|---|---|---|---|
| Enterprise Value | 9.65B 8.61B 7.93B 7.19B 13.63B 905B 13.97B 94.82B 37.79B 484B 36.22B 35.45B 1,525B | EV / Sales 2024 |
181x | EV / Sales 2025 | 492x |
| Free-Float |
10.55% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Avidity Biosciences, Inc.
| 1 day | +0.03% | ||
| Current year | +0.96% |
| Current year | 72 |  | 73.06 |
| 1 year | 69.77 | | 73.06 |
| 3 years | 5.15 | | 73.06 |
| 5 years | 4.82 | | 73.06 |
| 10 years | 4.82 | | 73.06 |
| Manager | Title | Age | Since |
|---|---|---|---|
John McKenna
PSD | President | - | 27/02/2026 |
Eduard Marti
TRE | Treasurer | - | 27/02/2026 |
Jaime S. Huertas
SEC | Corporate Secretary | - | 27/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Jaime S. Huertas
BRD | Director/Board Member | - | 27/02/2026 |
Eduard Marti
BRD | Director/Board Member | - | 27/02/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/2/26 | Issuer sale | Director | 110,073 | 0.0766% | ||
| 27/2/26 | Issuer sale | Chief Technology Officer | 547,865 | 0.3814% | ||
| 27/2/26 | Issuer sale | General Counsel | 302,054 | 0.2103% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | -.--% | +4.27% | +1,243.54% | 11.3B | |
| +4.28% | +0.07% | +46.07% | +138.78% | 1,206B | |
| +2.13% | +4.27% | +49.73% | +91.36% | 665B | |
| +0.68% | +1.54% | +34.10% | +112.47% | 515B | |
| +2.77% | -0.57% | +49.44% | +68.42% | 381B | |
| +1.38% | +0.27% | +71.48% | +45.30% | 362B | |
| +0.29% | -0.24% | +30.84% | +57.23% | 307B | |
| +0.98% | +0.76% | +9.04% | +38.31% | 289B | |
| +1.04% | -0.05% | +43.74% | +76.18% | 249B | |
| +1.46% | -0.59% | +43.31% | +125.82% | 207B | |
| Average | +1.18% | -1.38% | +38.20% | +199.74% | 419.1B | |
| Weighted average by Cap. | +2.12% | -1.95% | +43.63% | +99.30% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 10.9M 9.73M 8.95M 8.12M 15.39M 1.02B 15.78M 107M 42.67M 547M 40.9M 40.03M 1.72B | 18.76M 16.74M 15.4M 13.98M 26.5M 1.76B 27.15M 184M 73.45M 941M 70.4M 68.89M 2.96B |
| Net income | -322M -288M -265M -240M -455M -30.21B -467M -3.17B -1.26B -16.17B -1.21B -1.18B -50.94B | -685M -611M -562M -510M -967M -64.17B -991M -6.73B -2.68B -34.36B -2.57B -2.51B -108B |
| Net Debt | -1.49B -1.33B -1.23B -1.11B -2.11B -140B -2.16B -14.69B -5.85B -75.01B -5.61B -5.49B -236B | -1.65B -1.47B -1.35B -1.23B -2.33B -154B -2.39B -16.19B -6.45B -82.68B -6.18B -6.05B -260B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RNAM Stock
Select your edition
All financial news and data tailored to specific country editions
